BioVentrix to Exhibit Revivent™ System, which Surpasses Survival Benefit Threshold for Heart Failure Treatment, at European Heart Failure Congress
5/22/2013 11:08:03 AM
More...
|
BioVentrix Release: Updated "STICH" Study Concludes That Surgical Ventricular Reconstruction (SVR) in Conjunction with CABG Decreased Mortality by 64% in Heart Failure Patients Compared with CABG Procedure Alone at Four-Year Follow-up
1/28/2013 10:07:45 AM
More...
|
BioVentrix Appoints Industry Veteran Noel Messenger as Vice President of Regulatory & Clinical Affairs
1/2/2013 10:56:31 AM
More...
|
BioVentrix Receives CE Mark for Its Revivent® Myocardial Anchoring System
12/3/2012 8:45:51 AM
More...
|
BioVentrix Launches Novel Revivent Myocardial Anchoring System at Renowned European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
10/25/2012 9:06:04 AM
More...
|
BioVentrix Reports Favorable Patient Outcomes for Heart Failure Treatment at TCT 2012
10/23/2012 8:41:59 AM
More...
|
BioVentrix Initiates Phase II Study of Revivent System for Less Invasive Heart Failure Treatment in Western Europe
10/3/2012 9:16:00 AM
More...
|
BioVentrix Announces Newly Elected Members to Board of Directors
6/18/2012 9:26:53 AM
More...
|
BioVentrix Selected to Present at Prestigious EuroPCR Meeting
5/14/2012 8:07:14 AM
More...
|
Heart Failure Patients Demonstrate Impressive Improvement With Novel, Less Invasive Technique Using BioVentrix Therapy
4/23/2012 11:55:23 AM
More...
|
|